A detailed history of Strs Ohio transactions in Denali Therapeutics Inc. stock. As of the latest transaction made, Strs Ohio holds 17,400 shares of DNLI stock, worth $435,870. This represents 0.0% of its overall portfolio holdings.

Number of Shares
17,400
Previous 17,400 -0.0%
Holding current value
$435,870
Previous $404,000 25.25%
% of portfolio
0.0%
Previous 0.0%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 05, 2024

BUY
$14.96 - $23.22 $65,824 - $102,168
4,400 Added 33.85%
17,400 $404,000
Q1 2024

May 13, 2024

SELL
$15.83 - $23.35 $12,664 - $18,680
-800 Reduced 5.8%
13,000 $266,000
Q2 2023

Jul 31, 2023

SELL
$23.37 - $32.96 $189,297 - $266,976
-8,100 Reduced 36.99%
13,800 $407,000
Q1 2023

Aug 02, 2023

BUY
$21.91 - $32.67 $177,471 - $264,627
8,100 Added 58.7%
21,900 $504,000
Q1 2023

Apr 27, 2023

SELL
$21.91 - $32.67 $258,538 - $385,506
-11,800 Reduced 35.01%
21,900 $504,000
Q2 2022

Jul 25, 2022

BUY
$20.88 - $35.19 $58,464 - $98,532
2,800 Added 9.06%
33,700 $991,000
Q3 2021

Oct 22, 2021

SELL
$48.48 - $78.23 $14,543 - $23,469
-300 Reduced 0.96%
30,900 $1.56 Million
Q2 2021

Jul 26, 2021

BUY
$50.3 - $78.44 $231,380 - $360,824
4,600 Added 17.29%
31,200 $2.45 Million
Q1 2021

Apr 23, 2021

BUY
$53.8 - $81.53 $365,840 - $554,404
6,800 Added 34.34%
26,600 $1.52 Million
Q4 2020

Jan 25, 2021

BUY
$36.89 - $93.56 $291,431 - $739,124
7,900 Added 66.39%
19,800 $1.66 Million
Q2 2020

Jul 23, 2020

SELL
$16.01 - $28.82 $334,609 - $602,338
-20,900 Reduced 63.72%
11,900 $287,000
Q2 2019

Jul 25, 2019

BUY
$18.5 - $28.14 $606,800 - $922,992
32,800 New
32,800 $680,000
Q2 2018

Aug 06, 2018

SELL
$15.25 - $21.02 $70,150 - $96,692
-4,600 Closed
0 $0
Q1 2018

Apr 20, 2018

BUY
$15.36 - $24.8 $70,656 - $114,080
4,600 New
4,600 $90,000

Others Institutions Holding DNLI

About Denali Therapeutics Inc.


  • Ticker DNLI
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 134,174,000
  • Market Cap $3.36B
  • Description
  • Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. It offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidate, including BIIB122/DNL151, a small molecule inhibitor, which is in phase I and phase Ib clinical trials for the treatm...
More about DNLI
Track This Portfolio

Track Strs Ohio Portfolio

Follow Strs Ohio and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Strs Ohio, based on Form 13F filings with the SEC.

News

Stay updated on Strs Ohio with notifications on news.